IGEA Pharma N.V. / Key word(s): Annual Results02-May-2022 / 07:30 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.IGEA to get SIX approval to delay the 2021 annual report disclosureHoofddorp, the Netherlands, 2 May 2022. IGEA Pharm.
IGEA Pharma N.V. / Key word(s): Annual Results IGEA Pharma N.V.: IGEA to get SIX approval to delay the 2021 annual report disclosure 02-May-2022 / 07:30 CET/CEST Release of an ad hoc announcement
EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Research Update/Research Update IGEA Pharma N.V.: GBC AG PUBLISHES INITIAL EQUITY RESEARCH REPORT WITH BUY RECOMMENDATION AND PRICE TARGET OF EUR 1.05
IGEA Pharma N.V. / Key word(s): Research Update/Research Update25-Nov-2021 / 23:10 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.GBC AG PUBLISHES INITIAL EQUITY RESEARCH REPORT WITH BUY RECOMMENDATION AND PRICE TARGET OF EUR 1.05.
EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Agreement/Research Update IGEA Pharma N.V.: GBC AG TO START EQUITY COVERAGE OF IGEA PHARMA 04-Oct-2021 / 23:55 CET/CEST Release of an ad hoc announcement